These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus. Wan PK; Ryan AJ; Seymour LW Mol Ther; 2021 May; 29(5):1668-1682. PubMed ID: 33845199 [TBL] [Abstract][Full Text] [Related]
66. Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential. Pi YN; Qi WC; Xia BR; Lou G; Jin WL Front Immunol; 2021; 12():697083. PubMed ID: 34295338 [TBL] [Abstract][Full Text] [Related]
68. Computational Approaches for the Investigation of Intra-tumor Heterogeneity and Clonal Evolution from Bulk Sequencing Data in Precision Oncology Applications. Laganà A Adv Exp Med Biol; 2022; 1361():101-118. PubMed ID: 35230685 [TBL] [Abstract][Full Text] [Related]
69. Immunosuppressive Roles of Galectin-1 in the Tumor Microenvironment. Huang Y; Wang HC; Zhao J; Wu MH; Shih TC Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680031 [TBL] [Abstract][Full Text] [Related]
70. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy. Huang L; Xu H; Peng G Cell Mol Immunol; 2018 May; 15(5):428-437. PubMed ID: 29553135 [TBL] [Abstract][Full Text] [Related]
71. Adapting clinical paradigms to the challenges of cancer clonal evolution. Murugaesu N; Chew SK; Swanton C Am J Pathol; 2013 Jun; 182(6):1962-71. PubMed ID: 23708210 [TBL] [Abstract][Full Text] [Related]
73. High-throughput targeted long-read single cell sequencing reveals the clonal and transcriptional landscape of lymphocytes. Singh M; Al-Eryani G; Carswell S; Ferguson JM; Blackburn J; Barton K; Roden D; Luciani F; Giang Phan T; Junankar S; Jackson K; Goodnow CC; Smith MA; Swarbrick A Nat Commun; 2019 Jul; 10(1):3120. PubMed ID: 31311926 [TBL] [Abstract][Full Text] [Related]
74. Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment. Jiang Z; Liu Z; Li M; Chen C; Wang X EBioMedicine; 2019 Apr; 42():431-442. PubMed ID: 30935888 [TBL] [Abstract][Full Text] [Related]
75. Top 10 Challenges in Cancer Immunotherapy. Hegde PS; Chen DS Immunity; 2020 Jan; 52(1):17-35. PubMed ID: 31940268 [TBL] [Abstract][Full Text] [Related]
77. Natural killer cells in cancer biology and therapy. Wu SY; Fu T; Jiang YZ; Shao ZM Mol Cancer; 2020 Aug; 19(1):120. PubMed ID: 32762681 [TBL] [Abstract][Full Text] [Related]
78. Immunologic Gene Sets Reveal Features of the Tumor Immune Microenvironment and Predict Prognosis and Immunotherapy Response: A Pan-Cancer Analysis. Pan H; Pan J; Li P; Wu J Front Immunol; 2022; 13():858246. PubMed ID: 35493519 [TBL] [Abstract][Full Text] [Related]
79. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy. Rivadeneira DB; Delgoffe GM Clin Cancer Res; 2018 Jun; 24(11):2473-2481. PubMed ID: 29386217 [TBL] [Abstract][Full Text] [Related]
80. The hypoxic tumour microenvironment: A safe haven for immunosuppressive cells and a therapeutic barrier to overcome. Chang WH; Lai AG Cancer Lett; 2020 Sep; 487():34-44. PubMed ID: 32470490 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]